Orchestra BioMed
OBIO
Market cap $189M

5.00 USD

+0.02

0.40%

At close Oct 9, 4:00 PM EDT

1 day

0.40%

5 days

3.09%

1 month

-9.26%

3 months

-37.58%

6 months

2.25%

Year to date

-43.05%

1 year

-25.60%

5 years

-56.52%

About: Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Employees: 56

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

175% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 8

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

65% more capital invested

Capital invested by funds: $70.4M [Q1] → $116M (+$45.5M) [Q2]

9% more funds holding

Funds holding: 43 [Q1] → 47 (+4) [Q2]

2.36% more ownership

Funds ownership: 37.36% [Q1] → 39.72% (+2.36%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$14

180%

upside

Avg. target

$14.50

190%

upside

High target

$15

200%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Yi Chen 30% 1-year accuracy 3 / 10 met price target	180%upside $14	Buy Initiated	22 Aug 2024
B. Riley Securities Kyle Bauser 33% 1-year accuracy 1 / 3 met price target	200%upside $15	Buy Initiated	25 Jul 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.35 per share a year ago.

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2024 financial results and provided a business update.

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

Zacks Investment Research

Orchestra BioMed Holdings, Inc. (OBIO) Loses -25.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Orchestra BioMed Holdings, Inc. (OBIO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Orchestra BioMed Holdings, Inc. (OBIO) Loses -25.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Should You Buy?

Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research

Orchestra BioMed Holdings, Inc. (OBIO) Upgraded to Buy: Here's What You Should Know

Orchestra BioMed Holdings, Inc. (OBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Orchestra BioMed Holdings, Inc. (OBIO) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research

Wall Street Analysts Believe Orchestra BioMed Holdings, Inc. (OBIO) Could Rally 102.61%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 102.6% in Orchestra BioMed Holdings, Inc. (OBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Orchestra BioMed Holdings, Inc. (OBIO) Could Rally 102.61%: Here's is How to Trade

Zacks Investment Research

Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?

Orchestra BioMed Holdings, Inc. (OBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?

Zacks Investment Research

All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy

Orchestra BioMed Holdings, Inc. (OBIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy

Zacks Investment Research

Does Orchestra BioMed Holdings, Inc. (OBIO) Have the Potential to Rally 135.64% as Wall Street Analysts Expect?

The consensus price target hints at a 135.6% upside potential for Orchestra BioMed Holdings, Inc. (OBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Orchestra BioMed Holdings, Inc. (OBIO) Have the Potential to Rally 135.64% as Wall Street Analysts Expect?

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

NEW HOPE, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York, NY, June 4-6, 2024.

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

See News Rankings

Charts implemented using Lightweight Charts™